Methylisoindigo and Its Bromo-Derivatives Are Selective Tyrosine Kinase Inhibitors, Repressing Cellular Stat3 Activity, and Target CD133+ Cancer Stem Cells in PDAC

by Jana Tegethoff, Roland Bischoff, Sawsan Saleh, Biljana Blagojevic, Karl-Heinz Merz, Xinlai Cheng
Published 2017-09-01